Home Search

incyte - search results

If you're not happy with the results, please do another search

Incyte gains full rights to lymphoma drug

Incyte signed an asset purchase agreement with MorphoSys, which gives Incyte exclusive global rights for tafasitamab, marketed as Monjuvi in the U.S. “This new agreement with MorphoSys provides Incyte with exclusive global...

Agilent to provide Incyte with diagnostic technology used in drug development

Agilent Technologies Inc. reached an agreement with Incyte  to support with companion diagnostics the development and commercialization of Incyte’s hematology and oncology portfolio.  Agilent is based in northern California and has a large...

Incyte CEO offers glimpse into biopharma company

Incyte CEO Hervé Hoppenot put a human face on the biopharmaceutical company during the keynote speech at the annual meeting of the Delaware State Chamber of Commerce on Monday night. Hoppenot emphasized the company's...

Cancer drug start-up launched by former Incyte researchers gets $102 million in funding

Synnovation Therapeutics launched this week with $102 million in financing led by Third Rock Ventures with participation from Nextech, Lilly Asia Ventures, Sirona Capital, and Cormorant Asset Management. Former research executives of...

Friends opting for remodeled lower school after Incyte’s $50 million land deal falls through

Wilmington Friends School will shelve plans for a combined upper and lower school after pharma company Incyte dropped plans to purchase the lower school for an expansion project. The proposal had run into fierce...

Incyte drops plan to buy Wilmington Friends School property for $50 million

A long-running legal battle between neighbors and Incyte may be over, with the pharma company writing off $5.6 million over the planned purchase of a portion of the Wilmington Friends School site. In regulatory filings,...

Incyte reports higher earnings in third quarter

Incyte is on its way to becoming a pharmaceutical company with $4 billion in annual revenues. Zacks reported  Incyte earnings were slightly above estimates, with revenue below estimates. Third-quarter revenue totaled $919 million. Net income for the quarter...

Mandy Moore partners with Incyte to highlight treatment for a form of eczema

Incyte announced today its partnership with actress, singer, and songwriter Mandy Moore on Moments of Clarity, an educational initiative highlighting stories of people living with mild to moderate atopic dermatitis. Incyte is based near Wilmington. Moore...

Incyte CEO Hoppenot to keynote State Chamber Dinner in late January

Incyte Chairman and CEO Hervé Hoppenot is keynote speaker at the 187th Annual Dinner of the Delaware State Chamber of Commerce on Jan. 29. Incyte, a biopharmaceutical company with roots in Califonia and Delaware established...

Soccer great Mia Hamm partnering with Incyte

Mia Hamm, a two-time Olympic gold medalist and two-time FIFA Women’s World Cup Champion, has H with Delaware-based Incyte in raising awareness about bone marrow transplants. When Hamm was 25, she lost her brother, Garrett,...

Incyte’s skin condition cream shows positive results in late-stage children’s trial

Incyte reported positive results from a ruxolitinib cream (Opzelura) study in children 2-12 with atopic dermatitis (AD). The study showed significantly more patients treated with ruxolitinib cream met the goal than those...

Board of Adjustment rejects Incyte variance for expanded office campus

The New Castle County Board of Adjustment voted unanimously last week to deny Incyte’s request for an expansion that would not meet code requirements. Incyte expand its corporate complex to house its entire area...

Guest view: Citizens urge county panel to deny Incyte variance

(Submitted by Neighbors for Responsible Land Use. Other points of view are welcome. Send responses to drainey@delawarebusinessnow.com) Scores of concerned citizens voiced their opposition to Incyte’s latest request for a variance at an explosive meeting...

County board to consider Incyte expansion plan

The New Castle County Board of Adjustment will consider a variance for the expansion of Incyte Corp.'s headquarters and research center in the Alapocas neighborhood near Wilmington. Incyte is proposing a 400,000-square-foot building at its...

Incyte gets accelerated approval for skin cancer drug

The U.S. Food and Drug Administration (FDA) has received accelerated approval for Zynyz  (retifanlimab-dlwr), afor the treatment of adults with a rare form of skin cancer,- etastatic or recurrent locally advanced Merkel cell...

Incyte reports positive results in 2-year trial of drug used to treat loss of...

Incyte announced positive two-year results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura  (ruxolitinib) cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease...

Incyte’s 4th quarter results beat estimates

Incyte issued an upbeat 2022 earnings report as its block-buster Jackafi blood cancer drug soared past $2 billion in sales. The conmpany based near Wilmington has been working to add to its...

Incyte, early-stage company to launch trial of cancer drug combo

Incyte and Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced a clinical trial collaboration and supply agreement to investigate a combination of cancer drug candidates. “While monoclonal antibodies targeting PD‑L1 or PD-1...

Incyte reports promising results from drug that treats skin disease

Incyte announced that data from a late-stage trial the pivotal Phase 3 found ruxolitinib cream was able to lead to add pigment for those suffering from the skin disease vitiligo. The results were published in...

Incyte plans to acquire early-stage company focused on vitiligo skin disease

Incyte entered into an agreement to acquire Villaris Therapeutics  a start-up focused on the development of novel antibody therapeutics for the skin disease vitiligo. The disease leads to the loss of skin pigment. Incyte is based...